Author Correction: Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer

被引：0
|
作者：
Laura M. Spring
Hyo Han
Minetta C. Liu
Erika Hamilton
Hanna Irie
Cesar A. Santa-Maria
James Reeves
Peng Pan
Ming Shan
Yongqiang Tang
Julie R. Graham
Sebastien Hazard
Leif W. Ellisen
Steven J. Isakoff
机构：
[1] Massachusetts General Hospital and Harvard Medical School,Translational Discovery & Development
[2] Moffitt Cancer Center-McKinley Outpatient Clinic,undefined
[3] Mayo Clinic,undefined
[4] Sarah Cannon Research Institute/Tennessee Oncology,undefined
[5] Icahn School of Medicine at Mount Sinai,undefined
[6] Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,undefined
[7] Florida Cancer Specialists-South/Sarah Cannon Research Institute,undefined
[8] GSK,undefined
[9] Ludwig Center at Harvard,undefined
[10] EQRx,undefined
[11] Boston Pharmaceuticals,undefined
[12] Alkermes Incorporated,undefined
[13] Bicycle Therapeutics,undefined
来源：
Nature Cancer | 2022年 / 3卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1138 / 1138
相关论文
共 50 条
  • [1] Neoadjuvant niraparib in patients with HER2-negative, BRCA-mutated resectable breast cancer
    Spring, L. M.
    Han, H.
    Hamilton, E.
    Irie, H.
    Santa-Maria, C. A.
    Reeves, J.
    Pan, P.
    Shan, M.
    Tang, Y.
    Graham, J. R.
    Hazard, S.
    Ellisen, L. W.
    Isakoff, S. J.
    BREAST, 2021, 56 : S55 - S56
  • [2] Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer
    Spring, Laura M.
    Han, Hyo
    Liu, Minetta C.
    Hamilton, Erika
    Irie, Hanna
    Santa-Maria, Cesar A.
    Reeves, James
    Pan, Peng
    Shan, Ming
    Tang, Yongqiang
    Graham, Julie R.
    Hazard, Sebastien
    Ellisen, Leif W.
    Isakoff, Steven J.
    NATURE CANCER, 2022, 3 (08) : 927 - +
  • [3] Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer
    Laura M. Spring
    Hyo Han
    Minetta C. Liu
    Erika Hamilton
    Hanna Irie
    Cesar A. Santa-Maria
    James Reeves
    Peng Pan
    Ming Shan
    Yongqiang Tang
    Julie R. Graham
    Sebastien Hazard
    Leif W. Ellisen
    Steven J. Isakoff
    Nature Cancer, 2022, 3 : 927 - 931
  • [4] Pilot neoadjuvant study of niraparib in HER2-negative, BRCA-mutated resectable breast cancer
    Han, Hyo
    Liu, Minetta C.
    Hamilton, Erika
    Irie, Hanna
    Santa-Maria, Cesar A.
    Reeves, James
    Liem, Andre
    Naraine, Adrianna Milillo
    Nangia, Julie
    Page, David
    Duncan, Meghan
    Shan, Ming
    Tang, Yongqiang
    Graham, Julie R.
    Ellisen, Leif W.
    Isakoff, Steven
    Spring, Laura
    CANCER RESEARCH, 2020, 80 (04)
  • [5] Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer (Jul, 10.1038/s43018-022-00400-2, 2022)
    Spring, Laura M.
    Han, Hyo
    Liu, Minetta C.
    Hamilton, Erika
    Irie, Hanna
    Santa-Maria, Cesar A.
    Reeves, James
    Pan, Peng
    Shan, Ming
    Tang, Yongqiang
    Graham, Julie R.
    Hazard, Sebastien
    Ellisen, Leif W.
    Isakoff, Steven J.
    NATURE CANCER, 2022, 3 (09) : 1138 - 1138
  • [6] Relationship between circulating tumor DNA and response to neoadjuvant niraparib in HER2-negative, BRCA-mutated breast cancer
    Shan, Ming
    Spring, Laura
    Liu, Minetta C.
    Hamilton, Erika
    Irie, Hanna
    Santa-Maria, Cesar A.
    Isakoff, Steven J.
    Reeves, James
    Ellisen, Leif W.
    Lim, Lee P.
    Garg, Kavita
    Bertucci, Caterina
    Feng, Bin
    Zhang, Hailei
    Sun, Kaiming
    Graham, Julie R.
    Hofstatter, Erin
    Han, Hyo
    CANCER RESEARCH, 2022, 82 (04)
  • [7] Real-world clinical outcomes of patients with BRCA-mutated (BRCAm) HER2-negative metastatic breast cancer: A CancerLinQ® study
    Miller, Robert S.
    Mokiou, Stella
    Taylor, Aliki
    Jiang, Miao
    Sun, Ping
    McCutcheon, Susan
    CANCER RESEARCH, 2021, 81 (04)
  • [8] Indirect treatment comparison of olaparib and talazoparib in germline BRCA-mutated HER2-negative metastatic breast cancer
    McCrea, Charles
    Hettle, Robert
    Gulati, Poonam
    Taneja, Ankush
    Rajora, Preety
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2021, 10 (13) : 1021 - 1030
  • [9] Neoadjuvant Cisplatin in BRCA Carriers With HER2-Negative Breast Cancer
    Takamizawa, Shigemasa
    Ishiki, Hiroto
    Shimoi, Tatsunori
    Shimizu, Masaki
    Satomi, Eriko
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (23)
  • [10] ZEST: Randomized phase III study evaluating efficacy and safety of niraparib in patients with HER2-negative BRCA-mutated or triple-negative breast cancer with detectable circulating tumor DNA after definitive therapy
    Turner, Nicholas C.
    Cescon, David W.
    Loibl, Sibylle
    Janni, Wolfgang
    Rugo, Hope
    Balmana, Judith
    Crowley, Cheynna
    Chung, Jon
    Fucli, Giulia
    Hofstatter, Erin
    Frenkl, Tara
    Telli, Melinda L.
    CANCER RESEARCH, 2022, 82 (04)
12345